by admin | Dec 20, 2021 | press-releases
Home PRESS RELEASE CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of cretostimogene grenadenorepvecin Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin π» DESKTOP AUDIO PLAYER ===============================...
by admin | Nov 13, 2021 | press-releases
Home PRESS RELEASE CG Oncology Presents Preliminary Phase 2 Data with cretostimogene grenadenorepvec in Combination with pembrolizumab in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin π» DESKTOP AUDIO PLAYER ===============================...
by admin | Oct 12, 2021 | press-releases
Home PRESS RELEASE CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π± MOBILE AUDIO PLAYER...
by admin | Sep 22, 2021 | press-releases
Home PRESS RELEASE CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy cretostimogene grenadenorepvec as Part of Novel Combination for Various Solid Tumor Indications π» DESKTOP AUDIO PLAYER =============================== --> Listen to...
by admin | Sep 9, 2021 | press-releases
Home PRESS RELEASE CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy cretostimogene grenadenorepvec in Combination with nivolumab in Metastatic Urothelial Cancer π» DESKTOP AUDIO PLAYER...
by admin | Dec 10, 2020 | press-releases
Home PRESS RELEASE CG Oncology Closes $47 Million Series D Financing π» DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 π± MOBILE AUDIO PLAYER =============================== --> Listen to this article now 0:00 0.5x 0.75x Normal...